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Epidermal knockout of integrin b1 results in com-
plete disorganization of the basement membrane
(BM), resulting in neonatal lethality. Here, we report
that this disorganization is exacerbated by an
early embryonic inflammatory response involving
the recruitment of tissue-resident and monocyte-
derived macrophages to the dermal-epidermal
junction, associated with increased matrix metallo-
proteinase activity. Remarkably, the skin barrier in
the integrin b1 knockout animals is intact, suggest-
ing that this inflammatory response is initiated in a
sterile environment. We demonstrate that the mo-
lecular mechanism involves de novo expression of
integrin avb6 in the basal epidermal cells, which ac-
tivates a TGF-b1 driven inflammatory cascade re-
sulting in upregulation of dermal NF-kB in a Tenas-
cin C-dependent manner. Importantly, treatment of
b1 KO embryos in utero with small molecule inhib-
itors of TGF-bR1 and NF-kB results in marked
rescue of the BM defects and amelioration of im-
mune response, revealing an unconventional im-
muno-protective role for integrin b1 during BM
remodeling.INTRODUCTION
Integrity at the dermal-epidermal junction (DEJ) is critical
to maintaining skin homeostasis and barrier function. Basal
keratinocytes attach to the underlying extracellular matrix
(ECM) via heterodimeric transmembrane integrin receptors,
which activates bidirectional signaling cascades integral to
cellular processes such as proliferation, migration, and differ-
entiation (Hegde and Raghavan, 2013; Hynes, 2002; Marga-
dant et al., 2010). Epidermal basal keratinocytes are sepa-
rated from the underlying dermis by a contiguous basement3334 Cell Reports 16, 3334–3347, September 20, 2016 ª 2016 The A
This is an open access article under the CC BY-NC-ND license (http://membrane (BM) made up of an ordered array of ECM mole-
cules, which serve important structural and signaling func-
tions (Blanpain and Fuchs, 2009; Breitkreutz et al., 2013).
The major proteins that make up the epithelial BM are
collagen IV and laminin 332 (laminin 5), which require the
expression of ab1 integrins in the basal keratinocytes to orga-
nize (Brakebusch et al., 2000; deHart et al., 2003; DiPersio
et al., 1997; Raghavan et al., 2000). It is now well appreciated
that the ECM is not only important for structural rigidity, but is
also a major determinant of cellular behavior such as cyto-
skeletal reorganization, integrin signaling, and growth factor
signaling (Hynes, 2009). It is a dynamic reservoir for several
growth factors and cytokines released during development
or in response to injury (Hynes, 2009). ECM-remodeling en-
zymes such as matrix metalloproteinases (MMP) are key me-
diators of ECM plasticity (Visse and Nagase, 2003). MMP-
dependent remodeling of ECM is dysregulated in pathological
conditions like fibrosis and cancer (Bonnans et al., 2014; Cox
and Erler, 2011).
Apart from the physical barrier formed by the terminally differ-
entiated layers and underlying BM, it is well appreciated that the
innate and adaptive immune systems form a formidable barrier
to breaches and pathogenic infection throughout the lifetime of
an organism. The main classes of innate immune cells in the
skin are Langerhans cells, dendritic cells, tissue-resident macro-
phages, and circulating monocytes (Pasparakis et al., 2014).
Precursors of dendritic Langerhans cells are early infiltrates of
embryonic skin, and have been recently shown to be seeded
from the embryonic yolk sac as well as fetal liver (Hoeffel et al.,
2012). However, how these precursors and other immune cells
contribute to immune surveillance during embryonic skin devel-
opment is not completely understood. Most of our understand-
ing of fetal immune development at the body’s interface with
the surrounding is derived from studies of the gastrointestinal
system (McElroy and Weitkamp, 2011; Warner and Hamvas,
2015).
While the events that underlie a pathogen-driven inflamma-
tory response have been elucidated, less is known about how
inflammation is initiated by damage-associated molecular
patterns (DAMPs). This is also known as sterile inflammation,uthors.
creativecommons.org/licenses/by-nc-nd/4.0/).
since it occurs in the absence of any pathogens (Rock et al.,
2010). A defining feature of sterile inflammation is that it can
often result in chronic inflammatory diseases. For example,
long-term inhalation of particulates like asbestos can result
in the chronic activation of alveolar macrophages, resulting
in pulmonary fibrosis (Mossman and Churg, 1998). Likewise,
gout has been associated with accumulation of urate crystals
in the joints, resulting in extensive tissue damage due to an
acute inflammatory response mediated by neutrophils (Chen
and Nun˜ez, 2010). In ischemic-reperfusion injury commonly
seen in strokes and acute myocardial infarctions, the restora-
tion of blood flow paradoxically causes further tissue damage
by neutrophils due to release of DAMPs like reactive oxygen
species (ROS) from dying cells (Eltzschig and Eckle, 2011).
Endogenous antigens can also serve as DAMPs to elicit a
sterile inflammatory response mediated by Toll-like receptors
(TLRs) (Medzhitov, 2008; Srikrishna and Freeze, 2009).
Studies conducted in the context of chronic inflammation
have revealed the important role played by ECM-derived
DAMPs in eliciting an innate immune response that potenti-
ates adaptive immunity (Midwood and Orend, 2009). ECM
components, such as hyaluronic acid, heparan sulfate pro-
teoglycan (HSPG), and Tenascin C (TNC) are known to act
as proinflammatory DAMPs and can trigger inflammatory re-
sponses (Adair-Kirk and Senior, 2008; Goh et al., 2010).
TNC is expressed subepidermally in injured skin and precedes
inflammation (Chiquet-Ehrismann and Chiquet, 2003), indi-
cating the role ECM proteins and their degradation products
can play as potent inducers of inflammation. Importantly,
TNC expression is implicated in pathogenesis of autoimmune
diseases like rheumatoid arthritis and Crohn’s disease (Goh
et al., 2010).
There is a critical need to understand the earliest events that
set up sterile inflammation, which have remained elusive thus
far. This is important not only to understand the progression
of chronic inflammatory diseases, but also to design effective
therapeutic strategies for the same. These efforts have been
stymied to a large extent by the lack of appropriate model
systems.
In the present report, we have utilized the conditional integrin
b1 knockout (KO) mouse model to better understand the role
of sterile inflammation in remodeling the ECM during embry-
onic development. We report a unique inflammatory response
observed due to epidermis-specific loss of integrin b1 involving
aberrant recruitment of innate and adaptive immune cells, which
occurs in the presence of an otherwise intact skin barrier. This
immune response at the DEJ was found to be driven by TGF-
b1 production in proximal dermal fibroblasts and mediated by
de novo integrin b6 expression in basal epidermal cells. Using
in vivo drug administration experiments, we show the inflamma-
tory response to be defined by classical prostaglandin produc-
tion and be dependent on paracrine TGF-b signaling. Our report
clarifies some of the earliest events during prenatal sterile im-
mune responses and reveals an important role played by integrin
b1 in embryonic skin development. In doing so, our work sug-
gests the conditional b1 KO mouse can be exploited as a trac-
table model to study embryonic as well as pathophysiological
inflammation arising from aberrant remodeling.RESULTS
Loss of b1 in the Skin Epidermis Results in the
Upregulation of Proinflammatory Genes and Increased
MMP Activity at the DEJ Leading to a Progressive Loss
of ECM Organization
As previously reported, the conditional loss of b1 integrin (b1 KO)
in the epidermis leads to loss of BM organization and impaired
hair follicular morphogenesis (Raghavan et al., 2000). However,
several integrin-dependent and independent molecular events
in these animals have not been investigated. We followed the
loss of BM organization in the developing integrin b1 KO em-
bryos. Starting as early as embryonic day E16.5 there was a
marked disorganization of laminin 5 at the DEJ in b1 KO animals
(Figures 1Aand1B). This disorganization got progressivelyworse
by E18.5, resulting in a complete separation between the
epidermis and underlying dermis (Figures 1C–1F). We measured
the expression of other ECMcomponents like collagen IV, entac-
tin, fibronectin, andHSPGand found them tobe similarly disorga-
nized (Figures S1A–S1H). Additionally, we found keratin 6 (K6), a
known stress-response keratin (Lessard et al., 2013; Mazzalupo
et al., 2003), to be highly upregulated in the b1 KOepidermis (Fig-
ures S1I and S1J), suggesting that loss of integrin b1 in the
epidermis could result in adhesion defects eliciting a stress
response. The BM disruption observed in b1 KO skin samples
is much more severe when compared to related integrin KO
models such as integrin a6 or b4 KO (Dowling et al., 1996;
Georges-Labouesse et al., 1996; Raghavan et al., 2000). This
pointed to potentially additionalmolecular pathways contributing
to the severity of the adhesion-defect phenotype. We performed
next-generation sequencing (NGS) on RNA isolated from E18.5
wild-type (WT) and b1 KO skin and clustered enriched genes
based ongeneontology (GO). Interestingly,most of theGO terms
involved response to physiological processes such as inflamma-
tion, chemotaxis, and wound healing (Figure 1G). We validated
some of the highly upregulated genes (Table 1) by real-time
qPCR and subsequently classified them as inflammatory cyto-
kines (IL-18, IL-1b, IL-33, and IL-13), chemotactic chemokines
(CCL8,CCL20,CCL22,CXCL5, andCXCL16), andmetalloprotei-
nases in response to wounding (MMP 9 and 13) (Figure 1H). The
proinflammatory cytokines enriched in our analyses belong to
IL-1 family. These cytokines are predominantly produced by
monocytes, dendritic cells, and macrophages and are central
to their activation and proliferation (Arango Duque and Desco-
teaux, 2014). Chemokines such as CCL8 and CXCL5 are known
to be important for homing and trafficking of inflammatorymono-
cyte-derived macrophages (Mantovani et al., 2004). Notably,
macrophage-derived CXCL16 is integral to the activation of T
lymphocytes (Mantovani et al., 2004). This suggested that the
microenvironment of embryonic integrin b1 KO skin is flush with
chemotactic and proinflammatory factors which attract innate
andadaptive immunecells andpotentially sustain their response.
Since we found that various MMP RNAs were upregulated in
the integrin b1 KO skin (Table 1), and these have been shown
to be potent remodelers of the BM, we further analyzed if they
were in the active form or present as proenzymes.We performed
in situ zymography over progressive embryonic stages to assay
MMP activity at the DEJ in b1 KO mice. The progressivelyCell Reports 16, 3334–3347, September 20, 2016 3335
Figure 1. Progressive Loss in ECM Organization, Increased Expression of Inflammatory Molecules, and MMP Activity in b1 KO Embryos
(A–F) Distribution of b1 and Laminin 5 by immunofluorescence over later developmental stages. The asterisk denotes BM disruption and separation of epidermis
(Epi) from dermis (De).
(G andH) GO analysis of NGS of E18.5 whole skin fromWT and b1 KO (H) real-time qPCR of proinflammatory cytokines, chemokines, andwound-response genes
(the error bar represents SD). The fold change values of WT are normalized to 1 (data are representative of two independent replicates).
(I–N) In situ zymography performed on developmental stages of WT and b1 KO skin. The dotted line indicates DEJ. The scale bar represents 10 mm.
See also Figure S1.increasing ECM degradation (Figures 1B, 1D, 1F, and S1B) was
closely matched by higher MMP activity from E16.5 to E18.5
(Figures 1J, 1L, and 1N). Meanwhile, WT littermates had negli-
gible MMP activity at the DEJ (Figures 1I, 1K, and 1M). Interest-
ingly, there were no significant changes in protein or gene
expression of ECM components in the b1 KO animals (Figures
S1K and S1L). Collectively, these findings suggest that integrin
b1 KO embryos generate an inflammatory wound-response
signature and precipitate matrix remodeling at the DEJ, resulting
in loss of BM organization.
The Immune Infiltrate Recruited to the BM in Developing
Integrin b1 KO Skin Comprises of Tissue-Resident
Macrophages, Monocyte-Derived Macrophages, and
CD3+ T Lymphocytes
We next investigated if the increased expression of chemokines
and cytokines in the integrin b1 KO was associated with3336 Cell Reports 16, 3334–3347, September 20, 2016increased recruitment of immune cells during embryonic devel-
opment (E16.5 to E18.5). Compared to WT littermate controls,
we observed a distinct increase in the recruitment of both F4/
80+ (resident) and CD11b+ (monocyte-derived) macrophages
in the integrin b1 KO skin. F4/80+ tissue-resident macrophages
have been shown to home to the skin as early as E13.5 (Hoeffel
et al., 2012). We found a significant increase in the number of F4/
80+ cells recruited at the DEJ of integrin b1 KO skin compared to
theWT littermates by immunofluorescence (Figure 2A), corrobo-
rated with a 2-fold increase by flow cytometry (Figure 2B). We
found that the number of CD11b+ macrophages were signifi-
cantly higher in the integrin b1 KO skin as early as E16.5 (Fig-
ure 2C), where they formed the predominant immune infiltrate.
Flow cytometric analyses confirmed a 3-fold increase in the
CD11b+ populations of E18.5 integrin b1 KO skin (Figure 2D).
Interestingly, the recruitment of myeloid-monocytic cells was
observed to be followed by leukocytic infiltration around E17.5
Table 1. List of Genes Upregulated in NGS
Cytokines (Gene ID) Fold Change (p value < 0.05)
IL10 7.659
IL23a 4.892
IL12a 13.530
IL33 4.202
IL13 2.006
IL15 1.937
IL6 5.423
IL18 3.019
IL19 4.685
IL1a 3.243
IL1b 8.816
IL1f5 4.067
IL1f6 22.127
IL1f8 5.383
IL1f9 10.6289
Chemokines (Gene ID) Fold Change (p value < 0.05)
CCL1 2.203
CCL12 3.476
CCL17 2.141
CCl19 2.861
CCL2 4.157
CCL21b 2.231
CCL22 25.508
CCL25 1.574
CCL27a 4.193
CCL8 24.843
CCl9 2.831
CXCL1 7.547
CXCL10 2.927
CXCL11 2.053
CXCL16 1.633
CXCL2 18.452
CXCL5 75.181
CXCL9 1.534
MMPs (Gene ID) Fold Change (p value < 0.05)
MMP8 2.391
MMP9 7.336
MMP13 2.303
MMP3 2.825
MMP23 1.914
MMP28 2.215
MMP19 1.922(Figures 2E and 2F). The CD3+ immune cells that traffic to sites of
degradation include CD4+ and CD8+ T cells as well as gd T cells
(Figures S2A–S2I). Here also, there was a significant increase in
CD3+ cells by flow cytometry (Figure 2F). To further characterize
the immune cell infiltrate, we looked at mast cells, known to be
present in skin and mucosal tissue and responsible for allergic
inflammation characterized by high IgE secretion (Amin, 2012).Incidentally, we do not observe any changes in mast cell
numbers (Figures S2J–S2L), thus ruling out allergen-mediated
inflammation. Angiogenesis is often associated with inflamma-
tory diseases, aiding increased recruitment of immune cells to
the site of injury or infection (Varricchi et al., 2015). However,
we found that increased immune trafficking to the skin was not
due to angiogenesis (Figures S2M and S2N).
It has been shown that inflammatory responses in skin can be
attributed to loss of barrier integrity through aberrant terminal
differentiation programs (Lessard et al., 2013). Interestingly, b1
KO mice develop a normal epidermal barrier as experimentally
shown by toluidine blue staining (Figures 2G and 2H). Therefore,
an integrin b1 KO embryonic model is characterized by early
recruitment of proinflammatory cells, uniquely independent of
external damagecues suchasabarrier breachordefects in termi-
nal differentiation. We hypothesized that a paracrine recruitment
of immunepopulations couldbe thepotential source for theproin-
flammatory cytokine production and MMP activity, thus propa-
gating a damage response and eliciting local matrix remodeling.
The ECM Degradation Phenotype Is Exacerbated by
Immune Cells Recruited to the DEJ and Can Be
Ameliorated by the Use of Anti-inflammatory Drugs
To test our hypothesis that the inflammatory cascade produced
by the myelodominant infiltrate was responsible for ECM re-
modeling, we treated integrin b1 KO embryos with antiinflamma-
tory drugs. Specifically, pregnant ITGb1fl/fl mice (mated with
ITGb1fl/+:K14-Cremales giving integrin b1KOandWT littermates)
were administered with the NSAIDs aspirin and celecoxib for 3
consecutive days (corresponding to embryonic stages E15.5–
E17.5). NSAIDs target cyclooxygenases (COX), a class of proin-
flammatory enzymes responsible for high levels of prostaglandin
production during inflammation and pyrogenic responses (Baron
and Sandler, 2000; Dannenberg and Subbaramaiah, 2003). After
NSAID treatment, WT and b1 KO embryos were recovered from
drug-treated pregnant females at E18.5 and the impact on im-
mune response and ECM degradation was assessed. There
was no impact of NSAIDs or vehicle DMSO treatment on average
litter size or health of mother or pups (data not shown). Analyses
of dorsal skin tissue from drug-treated integrin b1 KO embryos
revealed a significant reduction in total numbers of F4/80+ tis-
sue-resident macrophages, CD11b+ monocyte-derived macro-
phages, and CD3+ T cells along with a marked reduction in
MMP activity at the DEJ, compared to vehicle-treated embryos
(Figures 3A–3L). This was corroborated with analyses of the im-
mune compartmentby flowcytometry, as evidencedbyanoverall
decrease in theCD3+T lymphocyteandmacrophagepopulations
upon NSAID treatment (Figure 3P). The reduction in dermal im-
mune infiltrate in NSAID-treated embryos was associated with a
significant amelioration of fragmented ECM (Figures 3M–3O).
Remarkably, the normalization of ECM in the drug-treated em-
bryos also resulted in de novo hair follicle morphogenesis, which
is otherwisedevelopmentally attenuated in the integrinb1KOskin
(Figures 3N and 3O). This suggested that the disruption of the BM
by the immune cells preceded the formation of hair placodes. We
verified that therewasno impact ofNSAID treatment onBMstruc-
tureor immune infiltration in treatedWT littermates (FigureS3).We
quantified the extent of phenotypic rescue by measuring theCell Reports 16, 3334–3347, September 20, 2016 3337
Figure 2. Increased Recruitment of Immune Cells in b1 KO in the Presence of Normal Barrier
(A) Expression of tissue-resident macrophage marker F4/80 (green) and Laminin 5 (red) from E16.5–E18.5 in WT and b1 KO embryos.
(B) FACS analysis of F4/80 population in E18.5 whole skin of WT and b1 KO embryos (n = 3; p value = 0.0256).
(C) Expression of monocyte-derived macrophage marker CD11b (green) and Laminin 5 (red) from E16.5–E18.5 in WT and KO b1 embryos.
(D) FACS analysis of CD11b population in E18.5 whole skin of WT and b1 KO embryos (n = 3; p value = 0.035).
(E) Expression of pan-T cell marker CD3 (green) and Laminin 5 (red) from E16.5–E18.5 in WT and b1 KO embryos.
(F) FACS analysis of CD3 population E18.5 whole skin of WT and b1 KO embryos (n = 3; p value = 0.0085).
(G and H) Toluidine blue dye-penetration assay of E17.5 WT and b1 KO embryos. The dotted lines indicate the upper most layer of skin in (A), (C), and (E).
epidermis (Epi), dermis (De). The scale bars represent 10 mm. Error bars represent SD.
See also Figure S2.disrupted distribution of ECM components by immunofluores-
cence. There was a significant reduction in BM disruption in
NSAID-treated b1 KO embryos, when compared to vehicle-
treated controls (Figure 3R). qRT-PCR analysis of skin from b1
KO embryos treated with NSAIDs showed marked downregula-
tion of inflammation-associated genes as well as MMPs associ-
ated with matrix remodeling (Figures 3Q, compare to 1H). Based
on the phenotypic rescue of inflammation-associated ECM
degradation by NSAIDs, we concluded that proinflammatory
prostaglandin-dependent cascades are likely mediators of this
embryonic remodeling. Notably, we show here that treating preg-
nant mice with NSAIDs can rescue ECM disruption phenotype,
MMP activity, and concomitant immune infiltration in developing
skin of in utero integrin b1 KO embryos.
The Strong Dermal Inflammatory Response in Integrin
b1 KO Embryos Is Driven via TGF-b1-TNC Pathway in an
Integrin b6-Dependent Manner
We have previously shown that conditional loss of integrin b1
results in a compensatory increase of integrin b6 in the3338 Cell Reports 16, 3334–3347, September 20, 2016epidermal compartment (Bandyopadhyay et al., 2012; Ragha-
van et al., 2003). In integrin b1 KO animals that display mosaic
expression of integrin b1 due to Cre inefficiency (MOS), we
found integrin b6 expression to be specifically upregulated in
regions lacking integrin b1 (Figure 4A), corroborating our previ-
ous reports. Notably, we observed the highest amount of
dermal immune infiltration in regions lacking epidermal integrin
b1 and instead expressing integrin b6 (Figure 4B). Based on
these data, we hypothesized that increased epidermal expres-
sion of integrin b6 upon conditional loss of integrin b1 triggers
proinflammatory cascades and associated matrix remodeling.
The relationship between integrin b6 and TGF-b1 is well estab-
lished in an inflammatory context (Henderson and Sheppard,
2013; Munger et al., 1999) and provided us with the rationale
to test the role of TGF-b1 signaling in potentiating the observed
immune response. Indeed, integrin b6 has been shown to bind
to the latency associated peptide (LAP) of TGF-b1 through its
RGD motif, causing the release of free TGF-b1 (Morris et al.,
2003; Munger et al., 1999; Yu and Stamenkovic, 2000). One
of the direct targets of TGF-b signaling in dermal fibroblasts
Figure 3. Treating b1 KO’s with NSAIDs Reduces Inflammatory Response and MMP Activity and Rescues the ECM Phenotype
(A–C) Expression of tissue-resident macrophage marker F4/80 (green) and Laminin 5 (red) in DMSO-, aspirin-, and celecoxib-treated KO embryos.
(D–F) Expression of monocyte-derived macrophage marker CD11b (green) and Laminin 5 (red) in DMSO-, aspirin-, and celecoxib-treated KO embryos.
(G–I) Expression of pan-T cell marker CD3 (green) and Laminin 5 (red) in DMSO-, aspirin-, and celecoxib-treated KO embryos.
(J–L) In situ zymography of DMSO-, aspirin-, and celecoxib-treated KO embryos.
(M–O) Tiled images of the expression of b1 (green) and Laminin 5 (red) in DMSO-, aspirin-, and celecoxib-treated embryos. Note that the expression of Laminin 5 is
significantly less spread in aspirin and celecoxib-treated embryos.
(P) FACS analysis of the total number of F4/80+, CD11b+, and CD3+ cells from whole skin samples taken at E18.5 from animals treated with DMSO, aspirin, or
celecoxib (* indicates p < 0.05 and ** indicates p < 0.01; n = 3) (the error bars indicate SD, N.D. denotes not detected).
(Q) qRT-PCR for cytokines, chemokines, and MMPs performed on RNA isolated from E18.5 whole skin of animals treated with DMSO, aspirin, or celecoxib. The
fold change values of WT are normalized to 1 (the error bars indicate mean ± SEM).
(R) Quantification of BM disruption N=atleast 10 flield; error bars indicate +/ SD. The dotted lines indicate the upper most layer of skin in (A), (I), and (M)–(O) and
DEJ in (J)–(L). epidermis (Epi), dermis (De). Arrowheads indicate leukocytes in A–L, nascent hair follicles in M–O. The scale bars represent 10 mm.
See also Figure S3.is TNC (Jinnin et al., 2004). We analyzed E16.5 embryonic skin
to elucidate the earliest molecular events associated with the
observable recruitment of immune cells and found regions of
high integrin b6 expression to co-localize with regions express-
ing TNC (Figures S4A and S4B). This was associated with
increased TGF-b1 in E16.5 integrin b1 KO skin compared
to WT (Figures S4C and S4D). We assayed for nuclear
pSMAD2/3 as a marker of active TGF-b1 signaling (Schmierer
and Hill, 2007) and observed abundant nuclear expression
in integrin b1 KO dermis as compared to WT, where it ismostly localized in the developing hair placodes (Figures S4E
and S4F).
To directly test the role of integrin b6 in activating TGF-b1 in b1
KO skin, we blocked the function of integrin avb6 in utero by us-
ing the functional blocking antibody 10D5 (Huang et al., 1998). To
target the antibody to the developing epidermis, we encapsu-
lated it in self-assembled liposomes consisting of cationic lipid
and DOPC (Figure S6). The liposomes containing 10D5 or the
IgG control were injected in utero into E14.5 b1 KO or WT em-
bryos and subsequently recovered E18.5 embryos for analysis.Cell Reports 16, 3334–3347, September 20, 2016 3339
Figure 4. Role of the Integrin b6-TGFb1-TNC Axis in Setting up the Inflammatory Response
(A) Expression of b1 (red), integrin b6 (green), and Laminin 5 (white) in back skin of E18.5 MOS. Note the reciprocity of the expression of b1 and integrin b6.
(B) Expression of F4/80 (green), integrin b6 (red), and Laminin 5 (white) in back skin of E18.5 MOS. Note that the immune infiltrate is associated with expression of
integrin b6 and loss of ECM organization.
(C and D) Expression of integrin b6 (green) and TNC (red) in back skin of E18.5 WT and b1 KO embryos.
(E and F) Expression of TGFb (green) in E18.5 WT and b1 KO embryos.
(G and H) Expression of TGFbR1 (red) and K5 (green) in E18.5 WT and b1 KO embryos.
(I and J) Expression of TNC (red) and TLR4 (green) in E18.5 WT and b1 KO embryos.
(K and L) Expression of K5 (white), F4/80 (green), andMyd88 (red) in E18.5WT and b1 KO embryos. Note that theMyd88 expression is seen in F4/80 positive cells
and in some basal cells.
(M and N) Expression of p65NF-kB (red) and K5 (green) in E18.5 WT and b1 KO embryos.
(O and P) Expression of K5 (green) and Cox2 (red) in E18.5 WT and b1 KO embryos. The dotted lines indicate the upper most layer of skin in all images except (E)
and (F), where it indicates DEJ. epidermis (Epi), dermis (De). The scale bar represents 10 mm.
(Q) RT-qPCR validation of b6-TGFb1-TNC pathway. The data are average of two independent replicates (the error bars indicate mean ± SD). TheWT fold change
values are normalized to 1.
(R) Immunoblot analysis with quantification of protein levels from E18.5 WT and KO whole skin.
(S) Model of b6-TGFb1-TNC axis in b1 KO embryos shows: (1) the upregulation of integrin b6 in epidermis of b1 KO embryos, (2) integrin b6 binds to TGFb1-LAP,
(3) TGF-b1 is released from its LAP upon binding to integrin b6 and binds a TGFbR1/TGFb-RII receptor dimer on extracellular binding domains, (4) TNC is localized
at the DEJ, (5) TNC binds TLR4/Myd88 in the dermis (primarily in the macrophages), (6) Proinflammatory cytokines are released by nuclear NF-kB driven
transcription resultin in, (7) the recruitment of additional tissue-resident and monocyte-derived macrophages, and (8) the release of active MMPs at the DEJ
resulting in remodeling of the BM.
See also Figures S4 and S6.10D5-injected embryos showed lower expression of TNC, extra-
cellular TGF-b1, and pSMAD2/3 compared to the IgG-treated
KO embryos (Figures S4J, S4K, S4N, S4O, S4R, and S4S), sug-
gesting that integrin b6 is a potent and direct activator of TGF-b1
in b1 KO animals. Interestingly, the ECM organization was also
rescued to some extent in the 10D5-treated embryos compared
to IgG control (Figures S4V and S4W). WT animals treated with
10D5 displayed lower levels of pSMAD2/3 in developing placo-
des compared to the IgG-treated controls (Figures S4P and3340 Cell Reports 16, 3334–3347, September 20, 2016S4Q) and generally displayed smaller hair placodes (Figures
S4I, S4M, and S4U) compared to the control (Figures S4H,
S4L, and S4T).
Several components of the TGF-b1 signaling pathway were
distinctly upregulated in the dermis of integrin b1 KO skin,
including TNC (Figures 4E–4H). TNC acts as a ligand for TLR4
to mediate inflammatory response via nuclear translocation of
the p65 subunit of NF-kB, leading to secretion of proinflamma-
tory chemokines (Midwood et al., 2009). We observed a distinct
TNC enrichment in the dermis of symptomatic integrin b1 KO
skin (Figures 4C and 4D), which was also corroborated by
qRT-PCR and protein expression (Figures 4Q and 4R). Down-
stream TLR4-dependent NF-kB signaling was found to be active
in integrin b1 KO dermis (Figures 4I–4N and 4R). qRT-PCR per-
formed on E16.5 integrin b1 KO skin showed enhanced expres-
sion of key players in this molecular pathway (Figure S4G), thus
corroborating active TLR signaling. Lastly, we verified that Cox2
expression was in fact higher in KO embryos, indicating the TLR-
mediated inflammatory cascade results in Cox2 expression in a
NF-kB-dependent manner (Figures 4O–4R). We thus provide
substantial evidence that the observed inflammatory cascade
in integrin b1 skin is triggered by expression of integrin b6 as
early as E16.5. Our model is that integrin b6 activates paracrine
TGF-b1 signaling in the vicinity of the BM, resulting in increased
expression of TNC by the underlying fibroblasts. TNC binds
TLR4/Myd88 (Midwood et al., 2009) predominantly in the dermal
compartment leading to nuclear NF-kB signaling. We hypothe-
size that NF-kB signaling in dermis leads to recruitment of
tissue-resident and circulating macrophages as well as effector
T lymphocytes to the DEJ, resulting in MMP activation and
remodeling of the BM of integrin b1 KO skin (Figure 4S).
In Utero Treatment of Integrin b1 KO Embryos with TGF-
bR1 Inhibitor Leads to Amelioration of ECM Disruption
and Immune Infiltration
In order to directly address the role of the TGF-b1 pathway in
setting up the observed ECM phenotype and associated im-
mune infiltration, we decided to target the pathway using a small
molecule inhibitor SD208 that specifically targets TGF-bR1 (Uhl
et al., 2004). We proceeded to modulate the availability of
TGF-b1 by injecting liposome-encapsulated SD208 (5 mg) into
pregnant female mice in utero. Remarkably, we observed a sig-
nificant rescue of ECM degradation upon administration of
SD208, when compared to control liposome-treated integrin
b1 KO embryos (Figures 5I, 5J, S5B, S5D, and S5U). This was
associated with a clear reduction in immune infiltration by T lym-
phocytes and macrophages (Figures 5A–5F, S5N, S5P, S5R,
S5T, S5V, and S5X). The expression of TNC and integrin b6,
which are direct targets of TGF-b1, are also greatly diminished
upon administering SD208 (Figures 5K, 5L, S5F, and S5H), indi-
cating efficacy of the treatment. As SD208 targets SMAD activa-
tion (Uhl et al., 2004), we assayed for activated pSMAD2/3 and
found it to be reduced in the dermis of SD208-treated b1 KO em-
bryos (Figures 5M, 5N, S5J, and S5L). There was much lower
pSMAD2/3 expression in WT embryos treated with SD208
when compared to vehicle, especially in the interfollicular
epidermis (Figures S5I and S5K). Interestingly, we also found
fewer hair placodes developing in the WT back skin, which
was expected since the TGF-b signaling pathway is important
for hair morphogenesis (Klopcic et al., 2007). Additionally, this
served as a control for the efficacy of TGF-b blocking by
SD208. We also observed a strong reduction in Myd88 and
NF-kB levels (Figures 5O–5R) and a marked reduction in MMP
activity by in situ zymography (Figures 5G and 5H). The expres-
sion of collagen IV, which was disrupted in the b1 KO, was
restored in the DEJ of SD-208-treated b1 KO animals (Figures
5S and 5T). Taken together, these data provide strong direct ev-idence for the role of paracrine the TGF-b1 pathway in setting up
the earliest events in the sterile inflammatory response observed
in integrin b1 KO embryos.
In Utero Treatment of Integrin b1 KO Embryos with
NF-kB Inhibitor Leads to Amelioration of ECMDisruption
and Immune Infiltration
Presence of TNC and activation of TLR4/Myd88 in b1 KO dermis
(Figures 4I–4N) is in line with previous reports of TNC activity as
an endogenous activator of TLR signaling (Midwood et al., 2009)
and provided us with a rationale to test the necessity of NF-kB
signaling in precipitating this dermal immune response. We
pharmacologically manipulated NF-kB signaling using a well-
known small molecule inhibitor Bay-11-7082, which efficiently
abrogates the DNA-binding ability of NF-kB (Mori et al., 2002). Li-
posomes containing Bay-11 (2.5 mg) or control liposomes were
injected in utero into E14.5 b1 KO and WT embryos and subse-
quently recovered at E18.5 for analysis. Therewere no significant
differences observed in numbers of immune cells, MMP activity,
ECM organization, or size of hair placodes in the Bay-11-treated
WT animals compared to the control-treated animals (Figures
6A–6R). However, we observed a significant rescue of the
ECM degradation in the Bay-11-treated b1 KO embryos (Figures
6S and 6T), associated with a decrease in T lymphocytes and
macrophages (Figures 6C–6L). MMP activity was also markedly
reduced in the Bay-11-treated embryos (Figures 6G and 6H).
Taken together, these data provide strong evidence for the role
of NF-kB in the inflammatory response seen in the KO embryos.
Altogether, we propose the followingmodel for how an embry-
onic inflammatory response may be capable of remodeling the
developing epithelial BM (Figure 7). In developing WT skin,
normal organization of the BM is maintained by the expression
of integrin b1. The normal prenatal immune contexture primarily
involves a modest pool of resident macrophages and naive
T cells, which form the early surveillance response. The loss of
epithelial integrin b1 is associated with severe BM disruptions
characterized by an increased recruitment of monocytes/macro-
phages and T cells and an increased activity of matrix remodel-
ing enzymes. Our data show that in the absence of integrin b1,
there is an upregulation of integrin avb6 in basal keratinocytes,
which in turn induces proinflammatory cytokine production in
the dermis. By treating the embryos with NSAIDs, we show
that this embryonic inflammatory cascade is the primary reason
behind BM remodeling. Paracrine TGF-b signaling at DEJ leads
to TNC-dependent activation of NF-kB in dermis, which results
in a ‘‘stress response’’ that drives prostaglandin production.
Such a danger signal drives infiltration of leukocytes into the
DEJ, promotes remodeling through secreted MMP activity, and
ultimately aggravates BM disruption.
DISCUSSION
Our study reveals somewhat unexpected insights into the mech-
anisms by which integrin b1 maintains epidermal homeostasis
and tissue integrity during development. The integrin b1 KO
model provides a unique platform to study the earliest events
involved in damage-associated sterile inflammation, the study
of which could have major implications in the treatment of skinCell Reports 16, 3334–3347, September 20, 2016 3341
Figure 5. In Utero Injection of SD-208 in b1 KO Embryos Rescues the ECM Phenotype
(A and B) Expression of tissue-resident macrophage marker F4/80 (green) and Laminin 5 (red) in vehicle-treated and SD-208-treated E18.5 b1 KO embryos.
(C and D) Expression of pan-T cell marker CD3 (green) and Laminin 5 (red) in vehicle-treated and SD-208-treated E18.5 b1 KO embryos.
(E and F) Expression of monocyte-derived macrophage marker CD11b (green) and Laminin 5 (red) in vehicle-treated and SD-208-treated E18.5 b1 KO embryos.
The arrows in (C)–(F) indicate localization of immune cells.
(G and H) In situ gelatin zymography in vehicle-treated KO and SD-208-treated E18.5 b1 KO embryos. The dotted lines indicate the DEJ.
(I and J) Tiled images of the expression of b1 (green) and Laminin 5 (red) in back skin of vehicle-treated and SD-208-treated E18.5 b1 KO embryos.
(K and L) Distribution of integrin b6 and TNC by immunofluorescence of vehicle- and SD-208-treated E18.5 b1 KO embryo.
(M and N) Expression of K5 (green) and pSMAD2/3 (red) in vehicle-treated and SD-208-treated E18.5 b1 KO embryos. Insets in M’ and N’ are higher magnifi-
cations of denoted areas in M and N.
(O and P) Expression of Myd88 (red) and K5 (green) in vehicle-treated and SD-208-treated E18.5 b1 KO embryos.
(Q and R) Expression of p65NF-kB (red) and K5 (green) in vehicle-treated and SD-208-treated E18.5 b1 KO embryos.
(S and T) Expression of b1 (green) and Col IV (red) in vehicle-treated and SD-208-treated E18.5 b1 KO embryos.
(U) Quantification of BM area in untreated b1 KO, vehicle-treated b1 KO, and SD-208-treated E18.5 b1 KO embryos. The error bars represent SEM.
** indicates p<0.01, N=atleast 10 fields; N.S. indicates not significant. The dotted lines indicate the upper most layer of skin in all images except (G) and (H), where
they indicate DEJ. epidermis (Epi), dermis (De). The scale bar represents 10 mm.
See also Figures S5 and S6.blistering disease and skin cancers. Specifically, this study es-
tablishes a direct link between the recruitment of phagocytic
cells and MMP-dependent remodeling of the BM during embry-
onic skin development. In doing so, we can reconcile the
exaggerated ECM-degradation phenotype with a non-mecha-
nosensory role for integrin b1 at the basal epidermis.
Although inflammatory responses in embryonic skin have not
been well characterized previously, there are published reports
of immune cell infiltration in embryonic skin of Ets1 transgenic
mice (Nagarajan et al., 2010) and in Involucrin, Envoplakin, and
Periplakin triple KO mice (Sevilla et al., 2007). However, both
these models display a loss-of-barrier phenotype and hence
are vulnerable to extrinsic insults and ensuing immune response.
In addition to embryonic models, the adult b1 KOmouse (Brake-
busch et al., 2000) also displayed defective hair growth, aberrant3342 Cell Reports 16, 3334–3347, September 20, 2016ECM production, and infiltration of F4/80+ macrophages and
T lymphocytes. It was suggested that the recruitment of immune
cells in the KO animals could be in response to malformed hair
follicles, but no direct correlation wasmade with ECM disorgani-
zation. To the best of our knowledge, this robust prenatal innate
immune response elicited by local damage-induced chemokine
cues, and set up in the presence of normal terminal differentia-
tion as well as an intact skin barrier, has not been previously
reported.
In this study, we demonstrate that the exaggerated ECM
degradation phenotype observed in integrin b1 KO epidermis
is the result of an unexpected embryonic inflammatory response.
This inflammatory response is triggered by the loss of integrin b1
in epidermal cells and associated with concomitant upregulation
of integrin b6. The role of integrin b6 in abnormal wound healing
Figure 6. In Utero Injection of Bay-11 in b1 KO Embryos Rescues the ECM Phenotype
(A–D) Expression of tissue-resident macrophage marker F4/80 (green) and Laminin 5 (red) in vehicle-treated and Bay-11-treated E18.5 WT and b1 KO
embryos.
(E–H) Expression of monocyte-derived macrophage marker CD11b (green) and Laminin 5 (red) in vehicle-treated and Bay-11-treated E18.5 WT and b1 KO
embryos.
(I–L) Expression of pan-T cell marker CD3 (green) and Laminin 5 (red) in vehicle-treated and Bay-11-treated E18.5 WT and b1 KO embryos.
(M–P) In situ gelatin zymography in vehicle-treated and Bay-11-treated E18.5 WT and b1 KO embryos.
(Q–T) Expression of b1 (green) and Laminin 5 (red) in vehicle-treated and Bay-11-treated E18.5 WT and b1 KO embryos. The dotted lines indicate the upper most
layer of skin in all images except (M)–(P), where they indicate DEJ. epidermis (Epi), dermis (De). The scale bar represents 10 mm.
See also Figure S6.and TGF-b mediated fibrosis (Ha¨kkinen et al., 2004) as well as
immunosuppression (Bandyopadhyay and Raghavan, 2009) is
well documented. In this study, we have further dissected the
lesser-known function of integrin avb6 in driving inflammation
in a non-cell autonomous manner via TGF-b signaling. Specif-
ically, we show that increased expression of integrin b6 in
b1-deficient cells activates TGF-b1 signaling, resulting in the up-
regulation of TNC expression. TNC serves not only as a ligand for
integrin b6, but also as a potent DAMP (Goh et al., 2010). The
TNC-TLR4-Myd88 axis in innate immune cells results in NF-kB
driven cytokine and chemokine production in the dermis. This,
in turn, leads to recruitment of monocytes/macrophages and T
lymphocytes, subsequent MMP activity, and an exaggerated
disruption of the ECM. Importantly, treatment of integrin b1KO
embryos with either antiinflammatory drugs (NSAIDs) or with
small molecular inhibitors of TGF-bR1 and NF-kB resulted in a
marked reversal of ECM defects, suggesting an unexpected
role for integrin b1 in epidermal immune homeostasis by regu-
lating activity/expression of integrin b6 and TGF-b1 effectors.
The role of inflammatory immune cells in ECM remodeling is
well known in the context of diseases like rheumatoid arthritis
(RA), osteoarthritis (OA), and several cancers (Lu et al., 2011).There is mounting evidence that suggests that individuals with
chronic inflammatory diseases such as pancreatitis and Crohn’s
disease are predisposed to developing certain cancers (Cous-
sens and Werb, 2002). This has been attributed to the persis-
tence of proinflammatory stromal cells that can potentiate and
shelter neoplastic lesions. Tumor-associated macrophages
(TAMs) and immature granulocytes have been shown to produce
excessive protumorigenic cytokines as well as remodeling
enzyme MMP9, resulting in disruption of the ECM as well as
enhanced growth factor processing (Chanmee et al., 2014;
Riabov et al., 2014). The resultant angiogenic spurt, increased
proliferation, and enhanced invasion contribute to aggressive
disease, thus underpinning the protumorigenic role of inflam-
matory ECM remodeling. It hence follows that drugs aimed at
limiting proinflammatory cascades can be promising as treat-
ment modalities. Indeed, several large-scale retrospective
studies suggest that cancer patients on long-term NSAID ther-
apy are protected from metastatic events (Algra and Rothwell,
2012; Rothwell et al., 2010). The in vivo NSAID experiments
described in our report successfully demonstrate that ECM
degradation in the b1 KO model is driven by classical prosta-
glandin-dependent inflammatory cascades. These experimentsCell Reports 16, 3334–3347, September 20, 2016 3343
Figure 7. Model of Integrin b1-Dependent
Inflammatory Cascade
Integrin b1 expression in the basal layer of the
epidermis is essential for structural integrity of the
ECM. The specific loss of b1 in keratinocytes re-
sults in an upregulation of b6 integrins that activate
the TGF-b pathway. Free TGF-b1 in the dermis
leads to increased production of the DAMP
TNC that activates TLR/Myd88 signaling in resi-
dent phagocytic populations. The recruitment of
proinflammatory cells leads to MMP-dependent
matrix disruption and underlies the b1 conditional
KO phenotype. Pharmacological blockade of in-
flammatory response using NSAIDs, as well as
targeted inhibition of the TGF-b pathway using
SD208 and NF-kB using Bay-11-7082 leads to
significant reduction of immune inflitration and
rescue of ECM disruption.also provide proof-of-concept for this unique mode of drug
administration that warrants further study.
Taken together, our work suggests a key role played by integ-
rin b1 in regulating tissue homeostasis and in maintaining an
immuno-protective microenvironment during tumultuous re-
modeling of the ECM during embryonic development. The integ-
rin b1 KO model also serves as a fantastic model to study early
events in sterile inflammatory diseases.
EXPERIMENTAL PROCEDURES
Animals
Generation of the b1 KO animals has been described elsewhere (Raghavan
et al., 2000). Animals of mixed background (C57BL6/CD1) were used for all ex-
periments. ITGb1fl/fl females and ITGb1fl/+;K14-Cre males were crossed to
collect embryos at different time points of gestation. Animal work was con-
ducted in the NCBS/inStem Animal Care Resource Center and at the
McLaughlin Research Institute, MT. All procedures were approved by the in-
Stem Institutional Animal Ethics Committee.
Flow Cytometry
E18.5 embryonic skin was treated with dispase (1 U/ml) for 1 hr at 37C to
separate the epidermis from dermis. The epidermis and dermis were then
treated with 0.025% trypsin and collagenase (0.2 mg/ml), respectively, to
obtain a single cell suspension. The cells (13 1010 cells/ml) were resuspended
in 100 ml of fluorescence-activated cell sorting (FACS) buffer (1% fetal bovine
serum [FBS], 0.1% NaN3 in 13 PBS). Incubation with primary antibodies
(30 min) and secondary antibodies (1 hr) at room temperature (RT) was fol-
lowed by PBS washes. The cells were resuspended in FACS buffer and
analyzed using a Beckman Coulter Gallios flow cytometer. The analysis of per-
centages of immune cell populations was performed using FlowJo v10
(FlowJo). Primary antibodies used were anti-F4/80, anti-CD3 (eBiosciences),
and anti-CD11b (Abcam). Secondary antibodies used were Alexa Fluor conju-
gated antibodies from Invitrogen (Thermo Fisher Scientific).
Immunofluorescence
10 mm cryosections of embryos were fixed for 10 min at RT in 4% paraformal-
dehyde or at 20C in 100% ice-cold acetone. This was followed by washes
with 13 PBS and permeabilization with PBST (0.2% Triton X-100 in PBS; or3344 Cell Reports 16, 3334–3347, September 20, 2016asmentioned in antibody datasheet). The sections
were blockedwith 5%normal donkey serum in 13
PBST for 1 hr and incubated with primary antibody
overnight. After washes with PBS, sections were
incubated with Alexa Fluor conjugated secondaryantibodies for 40 min at RT and mounted using Mowiol mounting medium.
The primary antibodies used were: antiintegrin b1, TNC, fibronectin, HSPG,
collagen IV, and entactin (Millipore); anti-CD3, F4/80, gdTCR, CD4, and CD8
(eBiosciences); anti-TLR4, Myd88, Cox2, and pSMAD2/3 (Abcam); NF-kb,
GAPDH (Cell Signaling); anti-TGF-b123 (R&D Systems); antilaminin 5 (332)
(gift from Bob Burgeson); anti-K5 (gift from Colin Jamora); antiintegrin b6 (gift
fromShelia Violette, Biogen Idec, Boston), and anti-K6 (gift fromSatrajit Sinha).
Images were acquired on a Zeiss LSM700 or LSM780 confocal microscope.
Toluidine Blue Staining for Mast Cells
The frozen sections were fixed in 4% paraformaldehyde. Toluidine blue stock
solution was made by dissolving 1 g of toluidine blue in 100 ml of 70% ethanol.
The sections were incubated for 3 min with toluidine blue stain working solu-
tion (pH 2.3), washed three times with distilled water, and mounted with DPX
mountant (Sigma-Aldrich).
Toluidine Blue Dye Penetration Assay
Whole-mount barrier assay was performed as described previously (Byrne
et al., 2010). Briefly, E18.5 embryos were treated in successive methanol gra-
dients (25%, 50%, 75%, 100%, 75%, 50%, and 25%), equilibrated with PBS
dipped in 1% toluidine blue dye for 30 s1 min and then destained in PBS until
pattern appeared. Embryos were embedded in 1% agar and photographed
using a dissection microscope at 43 magnification.
In Situ Zymography
Localized gelatinolytic activity of the MMP in unfixed cryosections of embryos
were determined by using DQ gelatin (Invitrogen) as a substrate. Frozen slides
were thawed for 5 min and washed with PBS twice for 5 min each to remove
OCT. This was followed by preincubation of slides in MMP activation buffer
(50 mM Tris-Hcl pH7.5, 150 mM NaCl, 5 mMCacl2, and 0.2 mM sodium azide)
or 20 mM EDTA (control) in an incubation chamber at 37C. Slides were then
incubated for 2 hr at 37C with DQ gelatin (1 mg/ml diluted 1:50 in activation
buffer), followed by three washes with PBS. Slides were then fixed with 4%
paraformaldehyde for 10 min and stained with DAPI and mounted in Mowiol
mounting medium (Sigma-Aldrich). Slides were imaged using a Zeiss
LSM700 or LSM 780 confocal microscope.
RNA Extraction and Real-Time qPCR
Total RNA was extracted from whole skin of WT and KO E16.5 and E18.5
embryos using TRIzol reagent (Invitrogen) according to manufacturer’s
instructions. Total RNA was dissolved in nuclease- free water and quantified
using Nanodrop (Thermo Scientific). 1 mg of total RNA was used to synthesize
cDNA using SuperScript III RT First Strand cDNA Synthesis Kit (Invitrogen).
Real-time PCRs were performed on an ABI7900HT system. mRNA expression
level was quantified by using the DDCt method and the gene expression was
normalized to GAPDH. The list of primers used is provided in Table S1.
Western Blotting
E18.5 whole skin tissue from WT and KO embryos was snap-frozen in liquid
nitrogen and pulverized using a tissue smasher. Tissue was resuspended in
RIPA lysis buffer (Sigma-Aldrich) with protease inhibitor cocktail (Roche) and
incubated on ice for 30 min. The lysates were sonicated and centrifuged at
high speed for 15 min. The protein was estimated using a BCA kit (Promega).
50 mg of total protein per lane was electrophoresed in sodium dodecyl sulfate
polyacrylamide gels (8%–10% SDS–PAGE) and transferred onto PVDF mem-
branes (Bio-Rad). The blots were blocked using 5% BSA and incubated with
primary antibody overnight at 4C. The blots were washed with 13 TBST
and incubated with HRP conjugated secondary antibodies for 1 hr at RT.
The blots were developed using chemiluminescence on ImageQuant LAS
4000 mini biomolecular imager.
Anti-inflammatory Drug Treatment
ITGb1fl/fl females and ITGb1fl/+;K14-Cre males were crossed as described
above. Pregnant females were started on the drug regimen when the embryos
were E15.5 from date of plug. Celecoxib (10 mg/kg) (Selleck Chemicals) and
aspirin (10 mg/kg) (Sigma-Aldrich) were dissolved in a vehicle of sunflower
seed oil (Cat 88921, Sigma-Aldrich) with 5% (w/v) DMSO (American Bio-
analytical). For 3 consecutive days (E15.5, E16.5, and E17.5), the mice were
weighed and appropriately calculated drug volumes were administered daily
by oral gavage using 1 ml gavage needle. Control animals were administered
vehicle alone at similar volumes for the same duration. For each of the treat-
ments at least ten females were treated with celecoxib, aspirin, or vehicle con-
trol. Embryos were recovered at E18.5 and either embedded in OCT or the
epidermis and dermis were separated and stored in RNAlater (Thermo Fisher)
for RNA isolation and qRT-PCR analysis.
InUtero Injections of TGF-bR1 Inhibitor SD-208, NF-kB Inhibitor Bay-
11-7082, and Integrin avb6 Blocking Antibody 10D5
0.5 mg of cationic lipid with cyclic (N,N’-dimyristyl cyclic 3,4-dihydroxy-pyrro-
lidinium) head group, 1 mg of DOPC (1,2-dioleoyl-sn-glycero-3-phosphocho-
line) (Avanti polar), and 250 mg of SD208/Bay-11-7082 (Sigma-Aldrich) was
dissolved in 80 ml of ethanol and 10% of Vitamin E TPGS (Sigma-Aldrich) at
80C in a glass vial. Milli-Q water was preheated to 80C. Water was slowly
added into glass vial containing lipid mixture under constant stirring condition
and continued vortex for 2–3 min at RT to produce multilamellar vesicles
(MLVs). MLVs were then sonicated in an ice bath until clarity using a Qsonica
Sonifier at 100% duty cycle and 5J output power to produce small unilamellar
vesicles (SUVs). The integrin avb6 blocking antibody 10D5 was encapsulated
in the following manner. To make 3.6 mM liposome, 2.124 mg of cyclic lipids
and 2.826 mg of DOPC were dissolved in chloroform (500 ml) in a glass vial.
The solvent was removed with a thin flow of moisture-free nitrogen gas and
the lipid filmwas kept for drying under high vacuum for 6 hr. 1ml of 5%glucose
solution was added to the vacuum dried lipid films and the mixtures were al-
lowed to swell overnight. The vials were then vortexed for 2–3min at RT to pro-
duce MLVs. MLVs were then sonicated in an ice bath until clarity using a
Qsonica Sonifier at 100% duty cycle and 5J output power to produce small
SUVs. 10 ml of liposome was added to 1 ml (2 mg/ml) of antibody integrin
avb6 blocking antibody 10D5 (gift from Dean Sheppard, UCSF) for in utero in-
jection. The amniotic fluid of embryos (E15.5) was injected either with the drug
or the vehicle control on the ventral side, where the placenta attaches. This al-
lowed the drug to be evenly distributed and absorbed by the skin before the
establishment of a terminal barrier. We recovered the injected embryos be-
tween E18E18.5 and analyzed skin phenotype as described elsewhere.
Statistical Analysis
Mean, SD, SEM, and statistical significance were calculated using GraphPad
v6.0e (Graphpad Software). Where appropriate, two-tailed unpaired t test orMann-Whitney U test was used for experiments involving only two groups
based on variance of data set, and two-way ANOVA was used for comparison
across multiple groups.
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